Lineage Cell Therapeutics Advances COR1 Program to Develop Off-the-Shelf Cell Therapy for Corneal Endothelial Disease
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf cell therapies for serious medical conditions, has announced significant progress in the preclinical development of COR1, its investigational corneal endothelial cell (CEnC) transplant program designed to treat corneal endothelial disease. The update highlights the company’s continued expansion into regenerative ophthalmology and demonstrates the potential of its proprietary manufacturing technologies to address one of the most pressing challenges in corneal transplantation—the limited availability of donor tissue.
The COR1 program is being developed as an allogeneic, pluripotent stem cell-derived therapy that aims to provide a scalable and standardized alternative to donor-derived corneal endothelial cells currently used in clinical practice. By leveraging its proprietary AlloSCOPE manufacturing platform, Lineage believes it can produce large quantities of high-quality corneal endothelial cells with greater consistency, improved availability, and longer shelf life than existing donor-based approaches.
The company also announced that it will discuss the latest developments surrounding the COR1 program during an investor conference call, where management will provide additional details regarding manufacturing progress, preclinical milestones, and future development plans.
Addressing a Critical Need in Corneal Transplantation
Corneal endothelial disease is a leading cause of vision impairment and blindness worldwide. The disease affects the innermost layer of the cornea, known as the corneal endothelium, whose primary function is to regulate fluid balance and maintain corneal clarity. Damage or loss of these specialized cells causes the cornea to swell, resulting in blurred vision, discomfort, and, in advanced cases, severe visual impairment requiring transplantation.
Although corneal transplantation has become a well-established treatment option, one of the greatest limitations remains the global shortage of donor tissue. Millions of patients worldwide could potentially benefit from corneal transplantation, yet the supply of donated corneas remains insufficient to meet demand.
Current donor-derived corneal endothelial cell therapies, including products approved in Japan, have demonstrated that transplantation of endothelial cells can successfully restore corneal function. However, these therapies rely entirely on cadaveric donor tissue, creating several challenges that limit widespread access.
Among these challenges are:
- Limited donor availability
- Variability in donor tissue quality
- Differences in cell viability between donors
- Complex processing and handling requirements
- Short storage life before transplantation
These limitations have encouraged researchers to explore stem cell-derived alternatives capable of providing a reliable and scalable source of therapeutic cells.
COR1: An Allogeneic Cell Therapy Designed for Broad Accessibility
Lineage’s COR1 program seeks to overcome these limitations through the use of pluripotent stem cell technology.
Rather than depending on donated human corneas, COR1 utilizes pluripotent stem cells that can be expanded and differentiated into corneal endothelial cells under carefully controlled manufacturing conditions.
The resulting transplant is designed as an allogeneic “off-the-shelf” therapy, meaning it can be manufactured in advance, stored, and made readily available for physicians when needed, eliminating dependence on donor tissue availability.
This approach offers several potential advantages over conventional donor-derived therapies, including:
- Consistent product quality
- Standardized manufacturing
- Large-scale production
- Reduced dependence on donor availability
- Simplified logistics
- Greater commercial scalability
- Potential cost efficiencies
According to Lineage, these characteristics could significantly improve patient access to corneal endothelial transplantation worldwide.
Leveraging the AlloSCOPE Manufacturing Platform
A key component of the COR1 program is Lineage’s proprietary AlloSCOPE manufacturing platform, which was developed to support scalable production of allogeneic cell therapies.
The platform’s name reflects its core objectives:
- Allogeneic
- Scalable
- Consistent
- Off-the-shelf
- Pluripotent cell Engineering
Using this manufacturing process, the company has successfully achieved seamless expansion of precursor cells within bioreactor systems before directing their differentiation into mature corneal endothelial cells.
Bioreactor-based manufacturing enables production under tightly controlled conditions while supporting significantly larger manufacturing volumes than traditional laboratory culture techniques.
Lineage believes this process can generate consistent batches of corneal endothelial cells suitable for clinical development and future commercial manufacturing.
Achieving Key Manufacturing Milestones
The company reported that COR1 has already met several important internal development milestones.
According to Lineage, the manufactured corneal endothelial cells have successfully demonstrated critical characteristics including:
- Appropriate cellular identity
- Desired potency
- Manufacturing consistency
- Commercially relevant scale
Meeting these internal benchmarks has provided sufficient confidence for the company to advance the program into the next stage of preclinical development.
Another notable achievement is the development of a thaw-and-inject formulation, which is intended to simplify treatment administration.
Unlike fresh donor tissue requiring immediate transplantation, a thaw-and-inject product could allow physicians to store the therapy until needed before preparing it for administration with minimal processing.
This feature could improve logistical flexibility while expanding access across treatment centers.
Transition into Animal Studies
Having reached these manufacturing objectives, Lineage has elected to move COR1 into in vivo preclinical animal testing.
These studies will evaluate several important characteristics of the investigational therapy, including:
- Cell survival
- Engraftment
- Safety
- Functional restoration of the corneal endothelium
- Overall therapeutic performance
The company expects initial data from these animal studies to become available later this year.
Successful completion of these studies would represent an important milestone supporting future regulatory discussions and eventual progression toward human clinical trials.
Leveraging Experience from Existing Ophthalmology Programs
The COR1 program builds upon Lineage’s extensive experience in regenerative ophthalmology.
The company has previously advanced OpRegen®, an investigational retinal pigment epithelial cell therapy being developed for geographic atrophy associated with age-related macular degeneration.
Through OpRegen and other pipeline programs, Lineage has developed substantial expertise in:
- Stem cell biology
- Ophthalmic cell manufacturing
- Quality control
- Clinical-grade production
- Regulatory development
Management believes these capabilities provide a strong foundation for advancing COR1 efficiently through preclinical and clinical development.
Potential for Large-Scale Commercial Manufacturing
One of the most significant aspects of the announcement involves manufacturing scalability.
Lineage stated that its planned two-tier Good Manufacturing Practice (GMP) banking system is expected to support production capable of generating millions of treatment doses.
Such production capacity would represent a major advantage over donor-derived therapies, where every transplant depends on a separate donated cornea.
The company also highlighted the recent implementation of its AlloSCOPE 5D manufacturing process, which is designed to further improve manufacturing efficiency while reducing production costs.
Large-scale automated production may ultimately help make regenerative ophthalmic therapies more broadly available and economically sustainable.
Executive Perspective
Brian M. Culley, Chief Executive Officer of Lineage Cell Therapeutics, emphasized the substantial unmet need facing patients with corneal endothelial disease.
He noted that millions of patients worldwide require corneal transplantation, yet donor tissue remains in critically short supply, with approximately one donor available for every 70 diseased eyes globally.
According to Culley, donor-derived endothelial cell therapies approved in Japan have already demonstrated that corneal endothelial cell transplantation can successfully restore vision, providing strong clinical validation for the therapeutic approach itself.
He explained that Lineage’s goal is not simply to replicate donor-derived therapies but to develop a more consistent, scalable, and cost-effective alternative capable of addressing the worldwide shortage of donor tissue.
Culley also highlighted the company’s successful use of the AlloSCOPE platform and proprietary pluripotent stem cell line to manufacture corneal endothelial cells that satisfy internal quality standards for identity, potency, and scalability.
He expressed optimism that upcoming animal studies, combined with continued manufacturing improvements, will further strengthen the development program.
The advancement of COR1 into animal testing marks an important step in Lineage Cell Therapeutics’ broader strategy of developing regenerative cell therapies capable of addressing diseases with significant unmet medical need.
If future studies continue to produce positive results, COR1 could offer a standardized, off-the-shelf alternative to donor-derived corneal endothelial cell transplantation, potentially expanding treatment access for millions of patients worldwide suffering from corneal endothelial disease.
With scalable manufacturing, proprietary stem cell technology, and growing expertise in ophthalmic regenerative medicine, Lineage aims to establish COR1 as a next-generation cell therapy designed to overcome many of the limitations associated with conventional donor-based transplantation while helping address the persistent global shortage of corneal donor tissue.
About the AlloSCOPE™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) Platform
The AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) platform highlights the key attributes of Lineage’s in-house technology and describes a differentiation and production modality from which Lineage can manufacture millions of doses of an allogeneic, cell-based product derived from a single initial pluripotent cell line, conferring consistent, cost-effective, and scalable cell-based production and which can be applied across multiple programs.
From our proprietary AlloSCOPE platform, we successfully completed a current Good Manufacturing Practice (“cGMP”) production run from a custom, two-tiered cell banking system, featuring a genetically-stable master cell bank (MCB) created from a single, well-characterized pluripotent cell line, which generated a working cell bank (WCB), which then provided the source material for two final cell-based product candidates. AlloSCOPE “5D” describes an application of AlloSCOPE with the goal of higher scale production with reduced manipulation.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf” cell therapies for serious medical conditions. Lineage’s programs are based on its proprietary cell-based technology platform, AlloSCOPE™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and associated development and manufacturing capabilities. From this proprietary AlloSCOPE platform, Lineage develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or substantially identical to cells found naturally in the human body.
These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages, and in some instances may be designed to have additional beneficial properties. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient’s functional activity.
Lineage’s pipeline currently includes: (i) OpRegen® cell therapy, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries;
(iii) ReSonanceTM (ANP1), an auditory neuronal progenitor cell therapy in preclinical development under a collaboration with William Demant Invest A/S for the potential treatment of auditory neuropathy;
(iv) PNC1, a photoreceptor neural cell therapy research initiative being evaluated for development for the potential treatment of vision loss due to photoreceptor dysfunction or damage;
(v) RND1, a novel hypoimmune induced pluripotent stem cell line being evaluated for development under a gene editing partnership;
(vi) ILT1, a cell therapy manufacturing initiative focused on the issue of large-scale production of undifferentiated pluripotent cells, which if successful could be evaluated for the production of islet cells to support a potential treatment of Type 1 Diabetes; and (vii) COR1, a corneal endothelial disease cell therapy in preclinical development for the potential treatment of corneal endothelial disease. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell.
About Corneal Endothelial Disease
Corneal endothelial cells form a semi-permeable barrier which allows for the selective passage of nutrients and solutes, while limiting bulk fluid flow. This layer of CEnCs keep the cornea properly hydrated and prevent excess fluid and molecules from entering the cornea. Barrier damage can lead to corneal swelling and vision loss. Corneal endothelial dystrophies are progressive conditions where cells on the inner layer of the cornea die, causing corneal swelling and subsequent and irreversible vision loss. The most common way to treat these is to replace the damaged cornea.
Fuchs endothelial corneal dystrophy (FECD) is the most common primary corneal endothelial dystrophy and the leading indication for corneal transplantation worldwide. FECD is characterized by the progressive decline of corneal endothelial cells (CEnC’s) and the formation of extracellular matrix (ECM) excrescences in the Descemet’s membrane (DM), called guttae, that lead to corneal edema and loss of vision.
FECD represents one of the largest underserved populations in ophthalmology, affecting approximately 7.33% of adults over 30 years of age globally, with the patient population projected to rise from approximately 300 million in 2020 to 415 million by 2050. The current addressable market spans 2-6 million patients in the United States and approximately 16 million in Europe. Globally, there is only 1 donor cornea available for every 70 diseased eyes that need one.
Over 13 million people worldwide are currently waiting for a corneal transplant, while global demand for keratoplasty reaches 12.7 million cases annually.Bullous keratopathy is caused by edema of the cornea, resulting from failure of the corneal endothelium to maintain the normally transparent, dehydrated state of the cornea.
Most frequently, it is due to Fuchs corneal endothelial dystrophy or to corneal endothelial trauma which can occur during intraocular surgery or after placement of a poorly designed or mispositioned intraocular lens implant. Cell therapy treatment for FECD is minimally invasive when compared to corneal transplant surgery and is currently administered via an injection into the anterior chamber of the eye (the fluid-filled space in front of the iris).
Following injection, the patient is supine for several hours to enable the cells to settle onto the back surface of the cornea (Descemet’s membrane). If successful, the new endothelial cells form a monolayer and restore the cornea’s fluid-pumping function, clearing the corneal edema.